Shandong Kexing Bioproducts Co. Ltd. A
Kexing Biopharm Co., Ltd., a biopharmaceutical company, engages in the research and development, production, and sale of recombinant protein drugs and microecological preparations in China, the European Union, Brazil, the Philippines, and Indonesia. The company focuses on oncology, immunology, and degenerative diseases; and develops new antibodies, proteins, nucleic acid drugs, and antiviral ther… Read more
Shandong Kexing Bioproducts Co. Ltd. A (688136) - Net Assets
Latest net assets as of September 2025: CN¥1.72 Billion CNY
Based on the latest financial reports, Shandong Kexing Bioproducts Co. Ltd. A (688136) has net assets worth CN¥1.72 Billion CNY as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥3.41 Billion) and total liabilities (CN¥1.70 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥1.72 Billion |
| % of Total Assets | 50.31% |
| Annual Growth Rate | 33.91% |
| 5-Year Change | -10.43% |
| 10-Year Change | N/A |
| Growth Volatility | 66.32 |
Shandong Kexing Bioproducts Co. Ltd. A - Net Assets Trend (2017–2024)
This chart illustrates how Shandong Kexing Bioproducts Co. Ltd. A's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Shandong Kexing Bioproducts Co. Ltd. A (2017–2024)
The table below shows the annual net assets of Shandong Kexing Bioproducts Co. Ltd. A from 2017 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥1.64 Billion | +0.52% |
| 2023-12-31 | CN¥1.63 Billion | -9.69% |
| 2022-12-31 | CN¥1.81 Billion | -5.49% |
| 2021-12-31 | CN¥1.91 Billion | +4.40% |
| 2020-12-31 | CN¥1.83 Billion | +162.82% |
| 2019-12-31 | CN¥696.34 Million | +40.83% |
| 2018-12-31 | CN¥494.46 Million | +132.98% |
| 2017-12-31 | CN¥212.24 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Shandong Kexing Bioproducts Co. Ltd. A's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 5.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥151.83 Million | 9.29% |
| Common Stock | CN¥199.64 Million | 12.21% |
| Other Comprehensive Income | CN¥34.48 Million | 2.11% |
| Other Components | CN¥1.25 Billion | 76.39% |
| Total Equity | CN¥1.63 Billion | 100.00% |
Shandong Kexing Bioproducts Co. Ltd. A Competitors by Market Cap
The table below lists competitors of Shandong Kexing Bioproducts Co. Ltd. A ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Urban Company Limited
NSE:URBANCO
|
$387.17 Million |
|
Schoeller-Bleckmann Oilfield Equipment Aktiengesellschaft
PINK:SBOEF
|
$387.18 Million |
|
Tus-Sound Environmental Resources Co Ltd
SHE:000826
|
$387.20 Million |
|
Nanjing Chemical Fibre Co Ltd
SHG:600889
|
$387.21 Million |
|
Prime Medicine, Inc. Common Stock
NASDAQ:PRME
|
$387.10 Million |
|
Ridley Corporation Limited
PINK:RIDYF
|
$387.08 Million |
|
Boss Energy Ltd
AU:BOE
|
$387.04 Million |
|
Apollo Micro Systems Limited
NSE:APOLLO
|
$387.02 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Shandong Kexing Bioproducts Co. Ltd. A's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 1,626,020,638 to 1,634,908,540, a change of 8,887,902 (0.5%).
- Net income of 31,480,895 contributed positively to equity growth.
- Dividend payments of 43,634,014 reduced retained earnings.
- Share repurchases of 31,125,100 reduced equity.
- Other comprehensive income increased equity by 34,483,596.
- Other factors increased equity by 17,682,525.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥31.48 Million | +1.93% |
| Dividends Paid | CN¥43.63 Million | -2.67% |
| Share Repurchases | CN¥31.13 Million | -1.9% |
| Other Comprehensive Income | CN¥34.48 Million | +2.11% |
| Other Changes | CN¥17.68 Million | +1.08% |
| Total Change | CN¥- | 0.55% |
Book Value vs Market Value Analysis
This analysis compares Shandong Kexing Bioproducts Co. Ltd. A's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.55x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 8.51x to 3.55x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | CN¥3.47 | CN¥29.49 | x |
| 2018-12-31 | CN¥8.09 | CN¥29.49 | x |
| 2019-12-31 | CN¥3.50 | CN¥29.49 | x |
| 2020-12-31 | CN¥9.21 | CN¥29.49 | x |
| 2021-12-31 | CN¥9.62 | CN¥29.49 | x |
| 2022-12-31 | CN¥9.10 | CN¥29.49 | x |
| 2023-12-31 | CN¥8.20 | CN¥29.49 | x |
| 2024-12-31 | CN¥8.31 | CN¥29.49 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Shandong Kexing Bioproducts Co. Ltd. A utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 1.93%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 2.24%
- • Asset Turnover: 0.44x
- • Equity Multiplier: 1.93x
- Recent ROE (1.93%) is below the historical average (8.48%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2017 | 27.98% | 9.64% | 0.83x | 3.50x | CN¥38.17 Million |
| 2018 | 19.04% | 10.57% | 1.04x | 1.73x | CN¥44.72 Million |
| 2019 | 22.95% | 13.42% | 1.01x | 1.69x | CN¥90.18 Million |
| 2020 | 7.60% | 11.40% | 0.52x | 1.29x | CN¥-43.87 Million |
| 2021 | 5.05% | 7.51% | 0.45x | 1.48x | CN¥-94.60 Million |
| 2022 | -4.99% | -6.86% | 0.42x | 1.75x | CN¥-271.13 Million |
| 2023 | -11.70% | -15.11% | 0.42x | 1.86x | CN¥-352.89 Million |
| 2024 | 1.93% | 2.24% | 0.44x | 1.93x | CN¥-132.01 Million |
Industry Comparison
This section compares Shandong Kexing Bioproducts Co. Ltd. A's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,043,310,248
- Average return on equity (ROE) among peers: 14.20%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Shandong Kexing Bioproducts Co. Ltd. A (688136) | CN¥1.72 Billion | 27.98% | 0.99x | $387.13 Million |
| Shenzhen CAU Technology Co Ltd (000004) | $124.02 Million | 4.50% | 1.13x | $80.66 Million |
| Pacific Shuanglin Bio pharmacy Co Ltd (000403) | $525.49 Million | 14.76% | 1.41x | $1.02 Billion |
| Nanhua Bio Medicine Co Ltd (000504) | $174.34 Million | 36.11% | 1.61x | $288.51 Million |
| Jiangsu Sihuan Bioengineering Co Ltd (000518) | $642.80 Million | -4.58% | 0.44x | $244.62 Million |
| Chengzhi Shareholding Co Ltd (000990) | $1.69 Billion | 3.06% | 0.97x | $850.04 Million |
| Hualan Biological EngineeringInc (002007) | $1.86 Billion | 32.78% | 0.08x | $2.00 Billion |
| Da An Gene Co Ltd of Sun Yat-Sen University (002030) | $2.09 Billion | 4.42% | 0.71x | $784.18 Million |
| Shanghai RAAS Blood Products Co Ltd Class A (002252) | $831.21 Million | 22.32% | 0.12x | $3.76 Billion |
| Baolingbao Biology Co Ltd (002286) | $2.04 Billion | 5.44% | 0.31x | $398.99 Million |
| Tibet Cheezheng Tibetan Medicine Co Ltd (002287) | $456.61 Million | 23.20% | 0.29x | $347.95 Million |